Results 131 to 140 of about 11,301 (165)

PCSK9 inhibitors reduces arterial stiffness in patients with acute coronary syndrome. [PDF]

J Med Biochem
Wang L, Wang R, Jiao T, Xu L, Ji E, Jiang Y, Wang Y, Liu Y, Li J.   +8 more
europepmc   +1 more source

Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in patients after percutaneous coronary intervention: a systematic review and meta-analysis. [PDF]

Front Cardiovasc Med
Cao Z, Chen N, Chen J, Xu X, Zhang Z, Wang Y.   +5 more
europepmc   +1 more source

Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A meta-analysis of randomized controlled trials. [PDF]

PLoS One
Zhang L, Li YY, Liu XH, Liu HJ, Xu Q.
europepmc   +1 more source

Effect of PCSK9 Inhibitors on Regulators of Lipoprotein Homeostasis, Inflammation and Coagulation. [PDF]

Biomedicines
Lunar P, Meglič H, Vehar M, Ugovšek S, Rehberger Likozar A, Šebeštjen M, Zupan J.   +6 more
europepmc   +1 more source

PCSK9 inhibitors: FOURIER study

Journal of Obesity & Weight Loss Therapy, 2018
openaire   +1 more source

PCSK9 Inhibitors and Anthracyclines: The Future of Cardioprotection in Cardio-Oncology. [PDF]

Hearts (Basel)
Repp ML, Edwards MD, Burch CS, Rao A, Chinyere IR.   +4 more
europepmc   +1 more source

Role of PCSK9 inhibitors in venous thromboembolism: current evidence and unmet clinical needs. [PDF]

Eur Heart J Cardiovasc Pharmacother
Zuin M, Corsini A, Dalla Valle C, De Rosa C, Maloberti A, Mojoli M, Rizzo M, Ciccirillo F, Madrid A, Riccio C, Grimaldi M, Colivicchi F, Oliva F, Temporelli PL, Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Working Group on Cardiological Chronicity.   +14 more
europepmc   +1 more source

Impact of a Physician-led Strike Early-Strike Strong Lipid-Lowering Protocol Incorporating PCSK9 Inhibitors for Patients with Acute Myocardial Infarction. [PDF]

J Atheroscler Thromb
Arai R, Hotsubo Y, Nakajima Y, Sumida R, Mizobuchi S, Migita S, Tanaka Y, Hori K, Fukumoto K, Ebuchi Y, Kojima K, Sudo M, Okumura Y.   +12 more
europepmc   +1 more source

Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipid Profile and Cardiovascular Events in High-Risk Diabetic Patients. [PDF]

Cureus
Patra V, Yella VR, Konda VGR, Sayana SB, Siripuram C, Konka S, Kandimalla R.   +6 more
europepmc   +1 more source

Rationale for Early Administration of PCSK9 Inhibitors in Acute Coronary Syndrome. [PDF]

Rev Cardiovasc Med
Giordano S, Ielapi J, Salerno N, Cersosimo A, Lucchino A, Laschera A, Canino G, Di Costanzo A, De Rosa S, Torella D, Sorrentino S.   +10 more
europepmc   +1 more source